Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab in Chronic Spontaneous Urticaria (CSU)
NCT06162728Phase 2Completed
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of briquilimab in chronic spontaneous urticaria (CSU), sponsored by Jasper Therapeutics, Inc.. Started Nov 2023; status: completed.
02
Drugs
briquilimab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06162728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162728.